THE MUSCLE QUESTION
Does retatrutide cause muscle loss?
The direct answer, from the verified record, is a neutral one. Retatrutide body-composition research indicates that fat mass decreases substantially, while some lean-mass reduction may also occur. The proportion should not be exaggerated into 'muscle destruction,' because DXA lean mass also includes water and non-muscle lean tissue.
In the only published retatrutide DXA dataset — the phase 2 body-composition substudy in type 2 diabetes ↗ — total fat mass fell by up to 26.1% at week 36, and the authors reported the lean-mass share of weight loss as similar to other obesity treatments. What this supports: fat mass is the dominant compartment lost on retatrutide. What it does not prove: that skeletal muscle is unaffected, that function is preserved, or that the same proportions hold in people without diabetes — the substudy measured neither muscle function nor bone, and 103 of 189 participants completed both DXA scans.
Why “lean mass” is not “muscle”
DXA reports lean soft tissue as one compartment. As Prado and Heymsfield’s imaging methodology review ↗ sets out, that compartment includes water and other non-muscle lean tissues — CT and MRI can distinguish them, DXA cannot. A DXA lean-mass decline during rapid weight loss is therefore a signal to investigate, not a direct measurement of lost skeletal muscle. This caveat governs every lean-mass figure quoted on this site.
The 35-trial systematic review of incretin and non-pharmacologic weight loss ↗ found a median ~28.3% of weight lost on incretin therapies attributable to muscle-based indices — and that no included study reported objective physical-function outcomes. The concern is quantified; the functional consequences are not.
Function is the under-measured endpoint
Rare functional data exist for semaglutide: the prospective SEMALEAN study ↗ (n=106 completers, single-arm) reported 13% weight loss at 12 months with lean-mass decline that stabilised after month 7, improved handgrip strength, and sarcopenic-obesity prevalence falling from 49% to 33%. What it supports: composition and function can diverge, and should be measured separately. What it does not prove: anything about retatrutide — it was an uncontrolled single-arm study of a different molecule.
For older adults, a scoping review on sarcopenia and sarcopenic obesity with GLP-1 receptor agonists ↗ documents the risk phenotype and cites protein intakes of 1.2–1.6 g/kg/day plus resistance training as mitigation — countermeasures from nutrition and exercise science, not from formulation design.
The RetaBone position
RetaBone does not claim that thiamine prevents retatrutide-associated muscle loss. No formulation component replaces adequate protein intake, resistance exercise, hydration and clinical monitoring. The research questions — how much lean mass, of what tissue, with what functional consequence, and under what nutritional support — are exactly the questions the RetaBone research agenda exists to keep visible. See also the full retatrutide lean-mass evidence review and the class-wide GLP-1 body-composition picture.